Asia Pacific Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity
- GRA3911707
- 133 Pages
- June 2020
- Healthcare
Highlighted with 38 tables and 65 figures, this 133-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2020-2026 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.
Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI
Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API
Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications
Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2015-2026 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2015-2026. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
Bayer Healthcare
Bioniche Animal Health
Boehringer Ingelheim
Bristol-Myers Squibb
Ceva Animal Health, Inc.
Elanco Animal Health
Eli Lilly and Company
F. Hoffmann-La Roche
Glaxosmithkline PLC
Heska Co.
Lonza Group
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Ranbaxy Laboratories
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.2 Major Growth Drivers 21
2.3 Market Restraints and Challenges 25
2.4 Emerging Opportunities and Market Trends 28
2.5 Porter’s Fiver Forces Analysis 32
3 Segmentation of Asia Pacific Market by Synthesis 36
3.1 Market Overview by Synthesis 36
3.2 Synthetic API 38
3.2.1 Branded Synthetic API 39
3.2.2 Generic Synthetic API 40
3.3 Biotech API 41
3.3.1 Biotech API by Drug Type 42
3.3.1.1 Monoclonal Antibodies 43
3.3.1.2 Recombinant Proteins 44
3.3.1.3 Vaccines 45
3.3.1.4 Other Biotech APIs 46
3.3.2 Biotech API by Customer Base 47
3.3.2.1 Innovative Biologic API 48
3.3.2.2 Generic Biosimilar API 49
3.3.3 Biotech API by Expression Technology 50
3.3.3.1 Mammalian Expression 51
3.3.3.2 Microbial Expression 52
3.3.3.3 Yeast Expression 53
3.3.3.4 Insect Expression 54
3.3.3.5 Other Expression Technologies 55
3.4 HPAPI 56
3.4.1 Branded HPAPI 57
3.4.2 Generic HPAPI 58
4 Segmentation of Asia Pacific Market by Manufacturing Process 59
4.1 Market Overview by Manufacturing Process 59
4.2 Captive Manufacturing 61
4.2.1 Branded Captive API 62
4.2.2 Generic Captive API 63
4.3 Merchant Manufacturing 64
4.3.1 Merchant Manufacturing by Drug Type 65
4.3.1.1 Branded Merchant API 66
4.3.1.2 Generic Merchant API 67
4.3.2 Merchant Manufacturing by Drug Synthesis 68
4.3.2.1 Merchant Synthetic API 69
4.3.2.2 Merchant Biotech API 70
5 Segmentation of Asia Pacific Market by Therapeutic Application 71
5.1 Market Overview by Therapeutic Application 71
5.2 Infectious Diseases 73
5.3 Oncology 74
5.4 Ophthalmology 75
5.5 Cardiovascular Disorders 76
5.6 Central Nervous System 77
5.7 Pulmonary Disorders 78
5.8 Orthopedics 79
5.9 Other Applications 80
6 Segmentation of Asia Pacific Market by Drug Type 81
6.1 Market Overview by Drug Type 81
6.2 Branded Prescription Drugs 83
6.3 Generic Prescription Drugs 84
6.4 OTC Drugs 85
7 Asia-Pacific Market 2019-2026 by Country 86
7.1 Overview of Asia-Pacific Market 86
7.2 China 89
7.3 Japan 91
7.4 India 94
7.5 Australia 96
7.6 South Korea 98
7.7 Rest of APAC Region 100
8 Competitive Landscape 102
8.1 Overview of Key Vendors 102
8.2 New Product Launch, Partnership, Investment, and M&A 105
8.3 Company Profiles 106
AbbVie Inc. 106
Astrazeneca 108
Aurobindo Pharma Ltd. 109
Bayer Healthcare 110
Bioniche Animal Health 111
Boehringer Ingelheim 112
Bristol-Myers Squibb 113
Ceva Animal Health, Inc. 114
Elanco Animal Health 115
Eli Lilly and Company 116
F. Hoffmann-La Roche 117
Glaxosmithkline PLC 118
Heska Co. 119
Lonza Group 120
Merck & Co., Inc. 121
Novartis International AG 122
Pfizer, Inc. 123
Ranbaxy Laboratories 124
Sanofi 125
Sun Pharmaceutical Industries Ltd. 126
9 Investing in Asia Pacific Market: Risk Assessment and Management 127
9.1 Risk Evaluation of Asia Pacific Market 127
9.2 Critical Success Factors (CSFs) 130
Related Reports and Products 133
Table 2. Main Product Trends and Market Opportunities in Asia Pacific Active Pharmaceutical Ingredients (API) Market 28
Table 3. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 36
Table 4. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2015-2026, $ bn 38
Table 5. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2015-2026, $ bn 42
Table 6. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2015-2026, $ bn 47
Table 7. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2015-2026, $ bn 50
Table 8. Asia Pacific Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2015-2026, $ bn 56
Table 9. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 59
Table 10. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2015-2026, $ bn 61
Table 11. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2015-2026, $ bn 65
Table 12. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2015-2026, $ bn 68
Table 13. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 71
Table 14. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2015-2026, $ bn 81
Table 15. APAC Active Pharmaceutical Ingredients (API) Market by Country, 2015-2026, $ bn 87
Table 16. China Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 90
Table 17. China Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 90
Table 18. China Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 90
Table 19. Japan Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 93
Table 20. Japan Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 93
Table 21. Japan Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 93
Table 22. India Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 95
Table 23. India Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 95
Table 24. India Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 95
Table 25. Australia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 97
Table 26. Australia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 97
Table 27. Australia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 97
Table 28. South Korea Active Pharmaceutical Ingredients (API) Market by Synthesis, 2015-2026, $ bn 99
Table 29. South Korea Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2015-2026, $ bn 99
Table 30. South Korea Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2015-2026, $ bn 99
Table 31. Active Pharmaceutical Ingredients (API) Market in Rest of APAC by Country, 2015-2026, $ bn 101
Table 32. AbbVie Inc.: Company Snapshot 106
Table 33. AbbVie Inc.: Business Segmentation 106
Table 34. AbbVie Inc.: Product Portfolio 107
Table 35. AbbVie Inc.: Revenue, 2016-2018, $ bn 107
Table 36. AbbVie Inc.: Recent Developments 107
Table 37. Risk Evaluation for Investing in Asia Pacific Market, 2019-2026 128
Table 38. Critical Success Factors and Key Takeaways 131
Similar Reports
This new 68-country report from LeadingMarketResearch.com is available by region, country, market segment, section, or individual test.
The report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the global blood banking market during the next five years, and assist industry executives in developing effective business, new ...
- Publish Date: March 2, 2020
- $0
Hearing aids in the form of analog units have been traditionally present and used in India. Digital hearing units are finding increased growth in acceptability owing to the changing perceptions and growing base of the target consumer group. The Indian market is largely dependent on imports from foreign countries; domestic players in the country are ramping up their manufacturing facilities. The gr...
- Publish Date: March 10, 2011
- $950
The Indian medical devices market is largely dependent on imports from foreign countries. Although domestic players in the country are ramping up their manufacturing facilities, the foreign companies continue to enjoy a superior market share on account of their brand recognition, reliability, and technological superiority. The growing target base of consumers will boost sales and the market is exp...
- Publish Date: July 18, 2011
- $950
